Paul Tudor Jones Nektar Therapeutics Transaction History

Tudor Investment Corp Et Al

$25.1 Billion
Q4 2024

A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Nektar Therapeutics stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 57,083 shares of NKTR stock, worth $53,087. This represents 0.0% of its overall portfolio holdings.

Number of Shares

57,083

Previous 57,083 -0.0%

Holding current value

$53,087

Previous $74,000 28.38%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.64 - $3.15 $133,596 - $657,543	-208,744 Reduced 78.53%	57,083 $40,000
Q4 2022 Feb 14, 2023	SELL	$2.03 - $4.28 $2,509 - $5,290	-1,236 Reduced 0.46%	265,827 $601,000
Q3 2022 Nov 14, 2022	SELL	$3.04 - $5.14 $658,844 - $1.11 Million	-216,725 Reduced 44.8%	267,063 $855,000
Q2 2022 Aug 15, 2022	BUY	$3.17 - $6.17 $35,187 - $68,487	11,100 Added 2.35%	483,788 $1.84 Million
Q1 2022 May 16, 2022	BUY	$4.16 - $13.72 $1.42 Million - $4.7 Million	342,422 Added 262.86%	472,688 $2.55 Million
Q4 2021 Feb 14, 2022	BUY	$10.83 - $18.41 $359,046 - $610,346	33,153 Added 34.14%	130,266 $1.76 Million
Q3 2021 Nov 15, 2021	SELL	$13.07 - $18.84 $1.06 Million - $1.52 Million	-80,746 Reduced 45.4%	97,113 $1.74 Million
Q2 2021 Aug 16, 2021	BUY	$16.52 - $20.4 $2.94 Million - $3.63 Million	177,859 New	177,859 $3.05 Million
Q1 2021 May 17, 2021	SELL	$16.56 - $25.46 $288,160 - $443,029	-17,401 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$15.77 - $19.03 $1.32 Million - $1.59 Million	-83,571 Reduced 82.77%	17,401 $296,000
Q3 2020 Nov 16, 2020	BUY	$16.59 - $24.79 $94,314 - $140,931	5,685 Added 5.97%	100,972 $1.68 Million
Q2 2020 Aug 14, 2020	BUY	$16.86 - $23.44 $935,949 - $1.3 Million	55,513 Added 139.57%	95,287 $2.21 Million
Q1 2020 May 15, 2020	SELL	$14.47 - $27.96 $1.44 Million - $2.79 Million	-99,780 Reduced 71.5%	39,774 $710,000
Q4 2019 Feb 14, 2020	BUY	$15.87 - $23.12 $2.01 Million - $2.93 Million	126,622 Added 979.14%	139,554 $3.01 Million
Q3 2019 Nov 14, 2019	BUY	$16.91 - $36.27 $218,680 - $469,043	12,932 New	12,932 $236,000
Q4 2018 Feb 14, 2019	SELL	$30.43 - $56.65 $188,452 - $350,833	-6,193 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$46.46 - $68.49 $4.78 Million - $7.05 Million	-102,878 Reduced 94.32%	6,193 $378,000
Q2 2018 Aug 14, 2018	BUY	$46.25 - $104.45 $5.04 Million - $11.4 Million	109,071 New	109,071 $5.33 Million

Others Institutions Holding NKTR

# of Institutions

152

Shares Held

131M

Call Options Held

92.7K

Put Options Held

4.9K

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $174M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track Paul Tudor Jones's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Account